WallStreetZenWallStreetZen

NASDAQ: DNAY
Codex Dna Inc Stock Forecast, Predictions & Price Target

Open Broker Account

Analyst price target for DNAY

Based on 1 analyst offering 12 month price targets for Codex Dna Inc.
Min Forecast
$8.00+376.19%
Avg Forecast
$8.00+376.19%
Max Forecast
$8.00+376.19%

Should I buy or sell DNAY stock?

Based on 1 analyst offering ratings for Codex Dna Inc.
Strong Buy
Strong Buy
1 analysts 100%
Buy
0 analysts 0%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their DNAY stock forecasts and price targets.

DNAY stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
KeyBanc
Top 11%
90
Strong BuyMaintains$8.00+376.19%2022-03-28

1 of 1

Forecast return on equity

Is DNAY forecast to generate an efficient return?
Company
N/A
Industry
24.26%
Market
122.06%

Forecast return on assets

Is DNAY forecast to generate an efficient return on assets?
Company
N/A
Industry
13.22%

DNAY earnings per share forecast

What is DNAY's earnings per share in the next 3 years based on estimates from 2 analysts?
Avg 1 year Forecast
-$1.87
Avg 2 year Forecast
-$1.27
Avg 3 year Forecast
-$0.30

DNAY revenue forecast

What is DNAY's revenue in the next 3 years based on estimates from 3 analysts?
Avg 1 year Forecast
$23.0M+34.26%
Avg 2 year Forecast
$44.8M+161.15%
Avg 3 year Forecast
$116.6M+579.69%
DNAY's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

DNAY revenue growth forecast

How is DNAY forecast to perform vs Medical Devices companies and vs the US market?
Company
57.14%
Industry
4.89%
Market
8.53%
DNAY's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
DNAY's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

DNAY vs Medical Device Stocks

TickerPricePrice TargetUp/downsideConsensus
DNAY$1.68$8.00+376.19%Strong Buy
NMRD$2.10$7.75+269.05%Strong Buy
ICCM$1.38$5.65+310.31%Strong Buy
SIEN$0.82$7.67+836.14%Strong Buy
TMDI$0.47N/AN/AHold

Codex Dna Stock Forecast FAQ

Is Codex Dna Stock a good buy in 2022, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NASDAQ: DNAY) stock is to Strong Buy DNAY stock.

Out of 1 analyst, 1 (100%) are recommending DNAY as a Strong Buy, 0 (0%) are recommending DNAY as a Buy, 0 (0%) are recommending DNAY as a Hold, 0 (0%) are recommending DNAY as a Sell, and 0 (0%) are recommending DNAY as a Strong Sell.

If you're new to stock investing, here's how to buy Codex Dna stock.

What is DNAY's earnings growth forecast for 2022-2024?

(NASDAQ: DNAY) Codex Dna's forecast annual earnings growth rate of N/A is not forecast to beat the US Medical Devices industry's average forecast earnings growth rate of 19.89%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 16.88%.

Codex Dna's earnings in 2022 is -$50,340,000.On average, 2 Wall Street analysts forecast DNAY's earnings for 2022 to be -$55,199,027, with the lowest DNAY earnings forecast at -$55,494,208, and the highest DNAY earnings forecast at -$54,608,663. On average, 2 Wall Street analysts forecast DNAY's earnings for 2023 to be -$37,488,109, with the lowest DNAY earnings forecast at -$38,373,655, and the highest DNAY earnings forecast at -$36,602,563.

In 2024, DNAY is forecast to generate -$8,855,459 in earnings, with the lowest earnings forecast at -$8,855,459 and the highest earnings forecast at -$8,855,459.

What is DNAY's revenue growth forecast for 2022-2024?

(NASDAQ: DNAY) Codex Dna's forecast annual revenue growth rate of 57.14% is forecast to beat the US Medical Devices industry's average forecast revenue growth rate of 4.89%, and and it is also forecast to beat the US market's average forecast revenue growth rate of 8.53%.

Codex Dna's revenue in 2022 is $17,155,000.On average, 3 Wall Street analysts forecast DNAY's revenue for 2022 to be $679,892,608, with the lowest DNAY revenue forecast at $664,159,410, and the highest DNAY revenue forecast at $711,388,524. On average, 3 Wall Street analysts forecast DNAY's revenue for 2023 to be $1,322,415,181, with the lowest DNAY revenue forecast at $1,018,377,762, and the highest DNAY revenue forecast at $1,579,223,486.

In 2024, DNAY is forecast to generate $3,441,821,654 in revenue, with the lowest revenue forecast at $3,441,821,654 and the highest revenue forecast at $3,441,821,654.

What is DNAY's forecast return on assets (ROA) for 2022-2025?

(NASDAQ: DNAY) forecast ROA is N/A, which is lower than the forecast US Medical Devices industry average of 13.22%.

What is DNAY's Price Target?

According to 1 Wall Street analyst that have issued a 1 year DNAY price target, the average DNAY price target is $8.00, with the highest DNAY stock price forecast at $8.00 and the lowest DNAY stock price forecast at $8.00.

The Wall Street analyst predicted that Codex Dna's share price could reach $8.00 by Mar 28, 2023. The average Codex Dna stock price prediction forecasts a potential upside of 376.19% from the current DNAY share price of $1.68.

What is DNAY's Earnings Per Share (EPS) forecast for 2022-2024?

(NASDAQ: DNAY) Codex Dna's current Earnings Per Share (EPS) is -$1.60. On average, analysts forecast that DNAY's EPS will be -$1.87 for 2022, with the lowest EPS forecast at -$1.88, and the highest EPS forecast at -$1.85. On average, analysts forecast that DNAY's EPS will be -$1.27 for 2023, with the lowest EPS forecast at -$1.30, and the highest EPS forecast at -$1.24. In 2024, DNAY's EPS is forecast to hit -$0.30 (min: -$0.30, max: -$0.30).

What is DNAY's forecast return on equity (ROE) for 2022-2025?

(NASDAQ: DNAY) forecast ROE is N/A, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.